DMD Digital Health Connections Group Inc (APTOF) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DMD Digital Health Connections Group Inc (APTOF) has a cash flow conversion efficiency ratio of 0.215x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.84 Million) by net assets ($-27.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See APTOF cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
DMD Digital Health Connections Group Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how DMD Digital Health Connections Group Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
DMD Digital Health Connections Group Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DMD Digital Health Connections Group Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ASOS Plc
LSE:ASC
|
0.700x |
|
SILVER HAMMER MINING CORP
F:7BW0
|
-0.026x |
|
Prima Alloy Steel Universal
JK:PRAS
|
0.006x |
|
Novra Technologies Inc
V:NVI
|
-0.231x |
|
AM Resources Corp
V:AMR
|
-3.051x |
|
Audeara Ltd
AU:AUA
|
0.024x |
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
-0.719x |
|
Wi2Wi Corporation
V:YTY
|
-0.128x |
Annual Cash Flow Conversion Efficiency for DMD Digital Health Connections Group Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of DMD Digital Health Connections Group Inc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see DMD Digital Health Connections Group Inc (APTOF) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-27.17 Million | $-21.99 Million | 0.809x | -89.78% |
| 2024-12-31 | $-4.54 Million | $-35.98 Million | 7.919x | -48.48% |
| 2023-12-31 | $-2.90 Million | $-44.59 Million | 15.371x | +1894.75% |
| 2022-12-31 | $37.74 Million | $-32.32 Million | -0.856x | -46.82% |
| 2021-12-31 | $74.24 Million | $-43.30 Million | -0.583x | -315.87% |
| 2017-12-31 | $21.54 Million | $5.82 Million | 0.270x | +48.67% |
| 2016-12-31 | $17.91 Million | $3.25 Million | 0.182x | -61.79% |
| 2015-12-31 | $10.30 Million | $4.90 Million | 0.476x | +123.52% |
| 2014-12-31 | $-1.56 Million | $3.16 Million | -2.023x | -72.51% |
| 2013-12-31 | $-3.10 Million | $3.64 Million | -1.173x | -- |
About DMD Digital Health Connections Group Inc
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloi… Read more